NASDAQ: ALECAlector Inc Stock
$5.09+0.02 (+0.39%)
Updated Apr 18, 2024
ALEC Price
$5.09
Fair Value Price
N/A
Market Cap
$487.36M
52 Week Low
$3.66
52 Week High
$9.07
P/E
-3.26x
P/B
3.63x
P/S
6.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$97.06M
Earnings
-$130.39M
Gross Margin
100%
Operating Margin
-128.97%
Profit Margin
-134.3%
Debt to Equity
3.64
Operating Cash Flow
-$184M
Beta
1.41
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ALEC Overview
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALEC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALEC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALEC is good value based on its book value relative to its share price (3.63x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
ALEC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALEC due diligence checks available for Premium users.
Be the first to know about important ALEC news, forecast changes, insider trades & much more!
ALEC News
Valuation
ALEC fair value
Fair Value of ALEC stock based on Discounted Cash Flow (DCF)
Price
$5.09
Fair Value
-$0.02
Undervalued by
30,865.02%
ALEC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALEC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.26x
Industry
15.68x
Market
41.33x
ALEC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.63x
Industry
5.76x
ALEC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALEC's financial health
Profit margin
Revenue
$15.2M
Net Income
-$41.4M
Profit Margin
-272.8%
ALEC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ALEC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$621.8M
Liabilities
$487.7M
Debt to equity
3.64
ALEC's short-term assets ($565.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALEC's short-term assets ($565.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALEC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALEC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$46.1M
Investing
$18.1M
Financing
$590.0k
ALEC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALEC vs Biotech Stocks
Alector Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.